By Sherri Oslick --
About
Court Report: Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.
Novartis Pharmaceuticals Corporation et al. v. Ranbaxy Inc. et al.
3:07-cv-03755; filed August 9, 2007 in the District of Court of New Jersey
Infringement of U.S. Patent No. 5,399,578 ("Acyl Compounds," issued March 21, 1995) following a paragraph IV certification as part of Ranbaxy's filing of an ANDA to manufacture a generic version of Novartis' Diovan® (valsartan, used to treat hypertension and heart failure). View the complaint here.
Eli Lilly and Company v. Actavis Elizabeth LLC
2:07-cv-03770; filed August 9, 2007 in the District of Court of New Jersey
Infringement of U.S. Patent No. 5,658,590 ("Treatment of Attention-Deficit/Hyperactivity Disorder," issued August 19, 1997) following a paragraph IV certification as part of Actavis' filing of an ANDA to manufacture a generic version of Lilly's Strattera® (atomoxetine hydrochloride, used to treat attention-deficit/hyperactivity disorder). View the complaint here.
Aventis Pharmaceuticals Inc. v. Mylan Pharmaceuticals, Inc.
2:07-cv-00345; filed August 9, 2007 in the Eastern District of Texas
Infringement of U.S. Patent No. 7,135,571 ("Processes for Preparing Anhydrous and Hydrate Forms of Antihistaminic Piperidine Derivatives, Polymorphs and Pseudomorphs Thereof," issued November 14, 2006) based on Mylan's manufacture and sale of generic Allegra® (fexofenadine hydrochloride, used to treat allergies). View the complaint here.
Comments